Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000593729 | SCV000706346 | uncertain significance | not provided | 2017-02-08 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000647529 | SCV000769325 | uncertain significance | Emery-Dreifuss muscular dystrophy 5, autosomal dominant | 2023-08-27 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 500415). This variant has not been reported in the literature in individuals affected with SYNE2-related conditions. This variant is present in population databases (rs138323662, gnomAD 0.009%). This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 5573 of the SYNE2 protein (p.Arg5573Trp). |
Ambry Genetics | RCV004024791 | SCV003672818 | uncertain significance | not specified | 2022-12-19 | criteria provided, single submitter | clinical testing | The c.16717C>T (p.R5573W) alteration is located in exon 91 (coding exon 90) of the SYNE2 gene. This alteration results from a C to T substitution at nucleotide position 16717, causing the arginine (R) at amino acid position 5573 to be replaced by a tryptophan (W). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |